Myriad Genetics sells Myriad RBM to Q2 Solutions

By The Science Advisory Board staff writers

May 25, 2021 -- Myriad Genetics is selling its Myriad RBM contract research services business to Q2 Solutions, a wholly owned subsidiary of Iqvia, for an undisclosed amount.

Myriad RBM specializes in contract research for the pharmaceutical industry and will be added to Q2 Solutions' testing, project management, supply chain, biorepository, biospecimen, and consent tracking solutions.

The divestiture of Myriad RBM will allow Myriad Genetics to accelerate its transformation plan and focus on the firm's core businesses in women's health, oncology, and mental health, Myriad said.

The agreement is subject to customary closing conditions and Myriad expects the transaction to close in the third quarter.

Altru Health adopts clinical trial AI from Deep Lens
Deep Lens and Altru Health System have announced a strategic collaboration that will deploy the Viper artificial intelligence (AI)-based clinical trial...
Cerecor licenses cytokine storm antibody from Kyowa Kirin
Cerecor has expanded an agreement with Kyowa Kirin for the exclusive worldwide rights to CERC-002, Kyowa Kirin's fully human anti-LIGHT (tumor necrosis...
Q2, Adaptive partner for clinical trial services
Q2 Solutions has announced a partnership with Adaptive Biotechnologies to use Adaptive's products in its clinical trial laboratory services.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter